{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","groups":[{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally \\[PO\\] on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 25 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG000","title":"V-DR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 15 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG001","title":"VDCR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.","id":"OG002","title":"V-DC"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.","id":"OG003","title":"VDC-mod"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population is defined as phase 2 patients with measurable disease at baseline and with at least 1 post baseline response assessment.","reportingStatus":"POSTED","timeFrame":"Up to 48 weeks or until disease progression","title":"Number of Patients With Stringent Complete Response Rate","type":"SECONDARY","unitOfMeasure":"participants"}